Related Experiment Video

Updated: Jul 7, 2026

The Use of Reverse Phase Protein Arrays (RPPA) to Explore Protein Expression Variation within Individual Renal Cell Cancers
12:22

The Use of Reverse Phase Protein Arrays (RPPA) to Explore Protein Expression Variation within Individual Renal Cell Cancers

Published on: January 22, 2013

Antibody therapy in renal cell carcinoma

Egbert Oosterwijk1, Otto C Boerman, Wim J C Oyen

  • 1267 Experimental Urology, University Medical Center St Radboud, Geert Grooteplein 26-28, 6525 GA Nijmegen, The Netherlands. e.oosterwijk@uro.umcn.nl

World Journal of Urology
|February 2, 2008
PubMed

Insights

Metastatic renal cell carcinoma (RCC) treatment remains challenging. Monoclonal antibodies (mAbs) targeting VEGF show promise as durable alternatives or adjuncts to tyrosine kinase inhibitors (TKIs) for RCC therapy.

Area of Science:

  • Oncology
  • Immunotherapy
  • Nephrology

Background:

  • Metastatic renal cell carcinoma (RCC) treatment is challenging despite tyrosine kinase inhibitors (TKIs).
  • Current therapies offer limited durability and can cause severe side effects.
  • Monoclonal antibodies (mAbs) represent a promising alternative treatment modality.

Purpose of the Study:

  • To review the potential of monoclonal antibodies (mAbs) in treating metastatic renal cell carcinoma (RCC).
  • To explore the role of Bevacizumab targeting vascular endothelial growth factor (VEGF) in RCC treatment.
  • To assess the efficacy of mAbs as single agents or in combination therapies for RCC.

Main Methods:

  • Review of current literature on RCC treatment modalities.
  • Analysis of studies involving monoclonal antibodies (mAbs) against RCC-associated antigens.
  • Evaluation of Bevacizumab's efficacy in inhibiting the VEGF pathway in RCC.

Main Results:

  • Monoclonal antibodies (mAbs) have shown promise in targeting RCC-associated antigens.
  • Bevacizumab, targeting vascular endothelial growth factor (VEGF), demonstrates positive outcomes, especially in combination therapies.
  • Tyrosine kinase inhibitors (TKIs) provide initial responses but lack durability and have significant side effects.

Conclusions:

  • Monoclonal antibodies (mAbs) may offer more durable responses in metastatic renal cell carcinoma (RCC) treatment.
  • Bevacizumab and other mAbs targeting VEGF are valuable additions to the RCC therapeutic arsenal.
  • Combination therapies involving mAbs could enhance treatment efficacy and patient outcomes for RCC.

More Related Videos

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody07:36

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Chronic Kidney Disease III: Interprofessional Care01:28

Chronic Kidney Disease III: Interprofessional Care

Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...